Compare Keramika Indonesia Assosiasi Tbk. (KIAS) vs Tempo Scan Pacific Tbk. (TSPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keramika Indonesia Assosiasi Tbk. vs Tempo Scan Pacific Tbk. — how do they compare? Keramika Indonesia Assosiasi Tbk. trades at Rp21 (market cap 313.51B), while Tempo Scan Pacific Tbk. trades at Rp2,730 (market cap 12.36T, 1.41M 24h volume). The key difference: Tempo Scan Pacific Tbk. is far larger — about 39.4× Keramika Indonesia Assosiasi Tbk.'s market cap. Which is the better fit depends on your goals.
| KIAS | TSPC | |
|---|---|---|
Market Cap | 313.51B | 12.36T |
Volume | — | 1.41M |
Lot | — | 14.08K |
Turnover | — | 3.83B |
Average Price | — | 2,722.04 |
Value | — | 3.83B |
Indicative Equilibrium Price | — | 2,730 |
Indicative Equilibrium Volume | — | 2.51K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keramika Indonesia Assosiasi Tbk.
KIA Group is one of the most diversified ceramic manufacturers in Indonesia, manufacturing Floor tiles (KSM), wall ties (KIA) and roof tiles (KKM). From their modest origins, a small ceramic tableware producer in the 1950s, KIA Group has to grown up to become Indonesias leading ceramic building material manufacturer. KIA Group received official recognition of its quality management system standard from SGS certification ISO 9002 no. Q4724 in 1995. In addition, KIA Group is in compliance with the World Bank Environmental and Social Policy Standard.
Read more on KIAS →About Tempo Scan Pacific Tbk.
PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Read more on TSPC →
